Topographic patterns of brain functional impairment progression according to clinical severity staging in 116 Alzheimer disease patients: FDG-PET study

Alzheimer Disease and Associated Disorders

Volumn 21, Issue 2, 2007, Pages 77-84

  Choo, Il Han ^a   Lee, Dong Young ^a   Youn, Jong Choul ^b   Jhoo, Jin Hyeong ^d   Kim, Ki Woong ^c   Lee, Dong Soo ^a   Lee, Jae Sung ^a   Woo, Jong Inn ^a,e  

^a Seoul National University   (South Korea)

^b Kyunggi Provincial Hospital for Elderly   (South Korea)

^c Seoul National University Bundang Hospital   (South Korea)

^d Kangwon National University College of Medicine   (South Korea)

^e Seoul National University Hospital   (South Korea)

Author keywords

Alzheimer disease; Cerebral metabolism; PET; Topographic pattern

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN REGION; CINGULATE GYRUS; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FRONTAL LOBE; GLUCOSE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NEUROPATHOLOGY; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; TEMPORAL LOBE;

AGED; ALZHEIMER DISEASE; BRAIN; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 34249934863     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0b013e3180687418     Document Type: Article

References (47)

1. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl). 1991;82:239-259.
2. DeKosky ST, Scheff SW. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann Neurol. 1990;27:457-464.
3. Perry EK, Tomlinson BE, Blessed G, et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978;2:1457-1459.
4. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991;30:572-580.
5. Jueptner M, Weiller C. Dose measurement of regional cerebral blood flow reflect synaptic activity? Implications for PET and fMRI. Neuroimage. 1995;2:148-156.
6. Sokoloff L. Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system. Fed Proc. 1981;40:2311-2316.
7. Duara R, Grady C, Haxby J, et al. Positron emission tomography in Alzheimer's disease. Neurology. 1986;36:879-887.
8. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 2002;17:302-316.
9. Mentis MJ, Alexander GE, Krasuski J, et al. Increasing required neural response to expose abnormal brain function in mild versus moderate or severe Alzheimer's disease: PET study using parametric visual stimulation. Am J Psychiatry. 1998;155:785-794.
10. Mielke R, Herholz K, Grond M, et al. Differences of regional cerebral glucose metabolism between presenile and senile dementia of Alzheimer type. Neurobiol Aging. 1991;13:93-98.
11. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med. 1994;35:391-398.
12. Pietrini P, Furey ML, Alexander GE, et al. Association between brain functional failure and dementia severity in Alzheimer's disease: resting versus stimulation PET study. Am J Psychiatry. 1999;156:470-473.
13. Ishii K, Mori T, Hirono N, et al. Glucose metabolic dysfunction in subjects with a clinical dementia rating of 0.5. J Neurol Sci. 2003;215:71-74.
14. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 1997;42:85-94.
15. Nestor PJ, Fryer TD, Smielewski P, et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol. 2003;54:343-351.
16. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method of grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
17. Tombaugh TN, McIntrye NJ. The mini-mental state examination: a comprehensive review. J Am Geriatr Soc. 1992;40:922-935.
18. Hughes CP, Berg L, Danziger W, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566-572.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
20. Mckhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task force on Alzheimer's disease. Neurology. 1984;34:939-944.
21. Lee JH, Lee KU, Lee DY, et al. Development of the Korean version of the Consortium to Establish a Registry for Alzheimer's Disease Assessment Packet (CERAD-K): clinical and neuropsychological assessment battery. J Gerontol Psychol Sci. 2002;57:47-53.
22. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology. 1989;39:1159-1165.
23. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43:2412-2414.
24. Minoshima S, Frey KA, Foster NL, et al. Preserved pontine glucose metabolism in Alzheimer disease: a reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 1995;19:541-547.
25. Friston KJ, Holmes AP, Worsley KJ, et al. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp. 1995;2:189-210.
26. Friston KJ, Frith CD, Liddle PF, et al. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab. 1991;11:690-699.
27. Forman SD, Cohen JD, Fitzgerald M, et al. Improved assessment of significant activation in functional magnetic resonance imaging (fMRI): use of a cluster-sized threshold. Mag Res Med. 1995;33:636-647.
28. Salmon E, Collette F, Degueldre C, et al. Voxel-based analysis of confounding effects age and dementia severity on cerebral metabolism in Alzheimer's disease. Hum Brain Mapp. 2000;10:39-48.
29. Garraux G, Salmon E, Degueldre C, et al. Comparison of impaired subcortico-frontal metabolic networks in normal aging, subcortical-frontal dementia, and cortical frontal dementia. Neuroimage. 1999;10:149-162.
30. Petit-Taboué MC, Landeau B, Desson JF, et al. Effects of healthy aging on the regional cerebral metabolic rate of glucose assessed with statistical parametric mapping. Neuroimage. 1998;7:176-184.
31. Talairach J, Tournoux P. Co-planar Stereotaxic Altlas of the Human Brain. New York: Thieme; 1988.
32. Lee DY, Lee KU, Lee JH, et al. A normative study of the CERAD neuropsychological assessment battery in the Korean elderly. J Int Neuropsychol Soc. 2004;10:72-81.
33. Haxby JV, Grady CL, Koss E, et al. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type. Neurology. 1988;38:1853-1863.
34. Kim EJ, Cho SS, Jeong Y, et al. Glucose metabolism in early onset versus late onset Alzheimer's disease: an SPM analysis of 120 patients. Brain. 2005;128:1790-1801.
35. Callen DJA, Black SE, Gao F, et al. Beyond the hippocampus: MRI volumetry confirms widespread limbic atrophy in AD. Neurology. 2001;57:1669-1674.
36. Paskavitz JF, Drachman DA, Hamos JE. Alterations in the dorsomedial nucleus of the thalamus in Alzheimer's disease. Neurology. 1990;20(suppl 1):339.
37. Pearce BR, Palmer AM, Bowen DM, et al. Neurotransmitter dysfunction and atrophy of the caudate nucleus in Alzheimer's disease. Neurochem Pathol. 1984;2:221-232.
38. Tiraboschi P, Hansen LA, Thal LJ, et al. The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology. 2004;62:1984-1989.
39. Ché telat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology. 2003;60:1374-1377.
40. Huang C, Wahlund LO, Almkvist O, et al. Cingulate cortex hypoperfusion predicts Alzheimer's disease in mild cognitive impairment. BMC Neurol. 2002;2:1-6.
41. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype. A prediction study with FDG-PET. Neurology. 2004;63:2332-2340.
42. Dickerson BC, Goncharova I, Sullivan MP, et al. MRI-based entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease. Neurobiol Aging. 2001;22:747-754.
43. Morris R, Petrides M, Pandya DN. Architecture and connections of retrosplenial area 30 in the rhesus monkey (macaca mulatta). Eur J Neurosci. 1999;11:2506-2518.
44. Garrido GEJ, Furuie SS, Buchpiguel CA, et al. Relation between medial temporal atrophy and functional brain activity during memory processing in Alzheimer's disease: a combined MRI and SPECT study. J Neurol Neurosurg Psychiatry. 2002;73:508-516.
45. Mosconi L, Tsui WH, De Santi S, et al. Reduced hippocampal metabolism in MCI and AD. Neurology. 2005;64:1860-1867.
46. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology. 1998;50:1585-1593.
47. Alexander GE, Chen K, Pietrini P, et al. Longitudinal PET evaluation of cerebral metabolic decline in Dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry. 2002;159:738-745.